Study treatment
PAD, REMISSION
Patients were initially assigned to VCD (bortezomib plus cyclophosphamide and dexamethasone), VTD (bortezomib plus thalidomide and dexamethasone), or PAD (bortezomib plus doxorubicin and dexamethasone) that was followed by Rd or Vd as continuous treatment once they achieved partial remission (PR) or better. VCD was comprised of 35-day cycles of subcutaneous bortezomib 1.3 mg/mThe consort diagram of reasons for the choice of the different “induction” triplets as well as the reasons for choosing Rd rather than Vd continuously